hotspot -WSS

hotspot

author：entertainment 2025-09-29 18:18:28 - browse：9

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Yancopoulos of Regeneron works to expand Dupixent success

focus

WSS

Biotech investment managers search for lucrative opportunities

Erich Jarvis studies song birds to learn about human stuttering

U.K. officials, researchers try to ease path for bespoke genetic treatments

Diabetes management: Digital health tools fall short, study says

How to ethically and practically extend health care to all

This gene therapy has record $4.25 million price. It's saved children.

knowledge

hotspot

knowledge

In Memoriam: Notable people who died in 2023

Physicians aren't 'burning out.' They're suffering from moral injury

Medicare details structure of new drug price negotiation program

Medicare Advantage insurers pressure Biden for bigger payments

Wildfire smoke exposes gaps in outdoor worker protections

Asbestos ban is immediate, but health effects will linger for decades

In age of alternative facts, a scholarly course on calling out crap

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Continuity nursing helped my family in our darkest PICU moments

Florida officials tell state schools to teach AP Psychology 'in its entirety'

knowledge

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Pregnancy ages women, but effects reverse after delivery

Physicians aren't 'burning out.' They're suffering from moral injury

Study links childhood stress with decline in older age

Steward Health Care expansion into Malta flopped

Yancopoulos of Regeneron works to expand Dupixent success

hotspot

leisure time

focus

focus